Impact of Medication Adherence on Work ... - Kantar Health

Hypertension <strong>Medication</strong> <strong>Adherence</strong> and Productivity
statistical analysis (SW, SG); provision <strong>of</strong> study materials or patients (FF-
T); obtaining funding (HL, FF-T); administrative, technical, or logistic
support (FF-T); and supervision (FF-T).
Address correspondence to: Shaloo Gupta, MS, Health Economics
and Outcomes Research, Kantar Health, 1 Independence Way, Ste 220,
Princeton, NJ 08540. E-mail: shaloo.gupta@kantarhealth.com.
REFERENCES
1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics
2009 update: a report from the American Heart Association Statistics Committee
and Stroke Statistics Subcommittee. Circulation. 2009;119(e):e21-e181.
2. Chobanian A, Bakris G, Black H. The Seventh Report <strong>of</strong> the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment <strong>of</strong> High Blood
Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
3. US Renal Data System, USRDS 2008 Annual Data Report: Atlas <strong>of</strong> Chronic
Kidney Disease and End-Stage Renal Disease in the United States. http://www
.usrds.org/atlas08.aspx. Published 2008. Accessed July 17, 2009.
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness,
treatment, and control <strong>of</strong> hypertension among United States adults 1999-2004.
Hypertension. 2007;49(1):69-75.
5. Kannan H, Thompson S, Bolge SC. Economic and humanistic outcomes associated
with comorbid type-2 diabetes, high cholesterol, and hypertension among
individuals who are overweight or obese. J Occup Environ Med. 2008;50(5):
542-549.
6. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Productivity costs associated
with cardiometabolic risk factor clusters in the United States. Value Health.
2007;10(6):443-450.
7. Bramley TJ, Gerbino PR, Nightengale BS, Frech-Tamas F. Relationship <strong>of</strong> blood
pressure control to adherence with antihypertensive monotherapy in 13 managed
care organizations. J Manag Care Pharm. 2006;12(3):239-245.
8. Elzubier AG, Husain AA, Suleiman IA, Hamid ZA. Drug compliance among
hypertensive patients in Kassala, eastern Sudan. East Mediterr Health J. 2000;
6(1):100-105.
9. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and
medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.
10. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. <strong>Impact</strong> <strong>of</strong> medication
adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):
521-530.
11. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs <strong>of</strong> interrupting
antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32(3):
214-226.
12. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients
by drug class: implications for health care costs. Clin Ther. 1997(6);19:
1446-1457.
13. Caro JJ, Speckman JL. Existing treatment strategies: does noncompliance
make a difference? J Hypertens. 1998;16(7):S31-S34.
14. Consumer Health Sciences. National Health and Wellness Survey. http://www
.chsinternational.com/nhws.html. Published 2008. Accessed June 16, 2009.
15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity <strong>of</strong> a selfreported
measure <strong>of</strong> medication adherence. Med Care. 1986;24(1):67-74.
16. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying
nonadherence with cardiovascular medications. Annals <strong>of</strong> Pharmacotherapy.
2004;38(9):1363-1368.
17. Kim E, Gupta S, Bolge S, Chen CC, Whitehead R, Bates JA. <strong>Adherence</strong> and
outcomes associated with copayment burden in schizophrenia: a cross-sectional
survey. J Med Econ. 2010;13(2):185-192.
18. Bates JA, Whitehead R, Bolge SC, Kim E. Correlates <strong>of</strong> medication adherence
among patients with bipolar disorder: results <strong>of</strong> the bipolar evaluation <strong>of</strong> satisfaction
and tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care
Companion J Clin Psychiatry. 2010;12(5).pii:PCC.09m00883.
19. Berni A, Ciani E, Cecioni I, Poggesi L, Abbate R, Boddi M. <strong>Adherence</strong> to antihypertensive
therapy affects Ambulatory Arterial Stiffness Index. Eur J Intern Med.
2011;22(1):93-98.
20. George J, Munro K, McCaig DJ, Stewart DC. Prescription medications: beliefs,
experiences, behavior, and adherence <strong>of</strong> sheltered housing residents. Ann Pharmacother.
2006;40(12):2123-2129.
21. Berry SD, Quach L, Procter-Gray E, et al. Poor adherence to medications may
be associated with falls. J Gerontol A Biol Sci Med Sci. 2010;65(5):553-558.
22. Ivanova JI, Birnbaum HG, Hsieh M, et al. <strong>Adherence</strong> to inhaled corticosteroid
use and local adverse events in persistent asthma. Am J Manag Care. 2008;
14(12):801-809.
23. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility <strong>of</strong> a work
productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):
353-365.
24. Reilly MA. Reilly Associates: WPAI Scoring. http://www.reillyassociates.net/
WPAI_Scoring.html. Published 2002. Accessed July 21, 2009.
25. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence
and subsequent healthcare utilization and costs. Am J Manag Care. 2010;
16(8):568-576.
26. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence
patterns among patients initiating therapy with the angiotensin II receptor antagonist
losartan versus other antihypertensive drug classes. Clin Ther. 2001;23(12):
1999-2010.
27. US Census Bureau. S2301. Employment Status: 2006-2008 American Community
Survey 3-Year Estimates. http://factfinder2.census.gov/faces/nav/jsf/
pages/index.xhtml. Published 2008. Accessed October 20, 2010.
28. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W.
Health, absence, disability, and presenteeism cost estimates <strong>of</strong> certain physical
and mental health conditions affecting U.S. employers. J Occup Environ Med.
2004;46(4):398-412.
29. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact <strong>of</strong> workplace productivity
losses due to allergic rhinitis compared with select medical conditions in
the United States from an employer perspective. Curr Med Res Opin. 2006;22(6):
1203-1210.
30. Rizzo JA, Abbott TA 3rd, Pashko S. Labour productivity effects <strong>of</strong> prescribed
medicines for chronically ill workers. Health Economics. 1996;5(3):249-226.
31. Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R.
Effects <strong>of</strong> initial antihypertensive drug class on patient persistence and compliance
in a usual-care setting in the United States. J Clin Hypertens. 2007;9(9):
692-700.
32. Van Wijk BLV, Klungel OH, Heerdink ER, de Boer Ad. Rate and determinants <strong>of</strong>
10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):
2101-2107.
33. Burnier M. <strong>Medication</strong> adherence and persistence as the cornerstone <strong>of</strong> effective
antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-1196.
34. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence
with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag
Care Pharm. 2003;9(5):424-429.
35. Burnier M, Hess B, Greminger P, Waeber B. Determinants <strong>of</strong> persistence in
hypertensive patients treated with irbesartan: results <strong>of</strong> a postmarketing survey.
BMC Cardiovasc Disord. 2005;5(1):13.
36. Gregoire JP, Moisan J, Guibert R, et al. Determinants <strong>of</strong> discontinuation <strong>of</strong>
new courses <strong>of</strong> antihypertensive medications. J Clin Epidemiol. 2002;55(7):
728-735.
37. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care
gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;
10(7, pt 2):481-486.
38. Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM.
Physician-related barriers to the effective management <strong>of</strong> uncontrolled hypertension.
Arch Intern Med. 2002;162(4):413-420.
39. Heisler M, Hogan MM, H<strong>of</strong>er TP, et al. When more is not better: treatment intensification
among hypertensive patients with poor medication adherence. Circulation.
2008;117(22):2884-2892.
40. Burton WN, Chen CY, Schultz AB, Edington DW. The prevalence <strong>of</strong> metabolic
syndrome in an employed population and the impact on health and productivity.
J Occup Environ Med. 2008;50(10):1139-1148.
41. Joshi AV, Madhavan SS, Ambegaonkar A, Smith M, Scott VG, Dedhia H. Association
<strong>of</strong> medication adherence with workplace productivity and health-related
quality <strong>of</strong> life in patients with asthma. J Asthma. 2006;43(7):521-526.
www.ajpblive.com
Vol. 4, No. 4 • The American Journal <strong>of</strong> Pharmacy Benefits e95